Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Fiche du document
- doi: 10.1007/s00228-019-02662-9
- issn: 0031-6970
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00228-019-02662-9
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30868192
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1432-1041
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_1B9CBBB244BC3
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
How to stop smoking Giving up smoking Smoking cessation programs Stopping smoking Quitting smoking Cigarette smoking cessation Influence and resultsCiter ce document
A. Glatard et al., « Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. », Serveur académique Lausannois, ID : 10.1007/s00228-019-02662-9
Métriques
Partage / Export
Résumé
The abstinence rate to tobacco after varenicline treatment is moderate and might be partially affected by variability in varenicline concentrations. This study aimed at characterizing the sources of variability in varenicline pharmacokinetics and to relate varenicline exposure to abstinence. The population pharmacokinetic analysis (NONMEM®) included 121 varenicline concentrations from 82 individuals and tested the influence of genetic and non-genetic characteristics on apparent clearance (CL/F) and volume of distribution (V/F). Model-based average concentrations over 24 h (Cav) were used to test the impact of varenicline exposure on the input rate (Kin) expressed as a function of the number of cigarettes per day in a turnover model of 373 expired carbon monoxide levels. A one-compartment model with first-order absorption and elimination appropriately described varenicline concentrations. CL/F was 8.5 L/h (coefficient of variation, 26%), V/F was 228 L, and the absorption rate (k a ) was fixed to 0.98 h -1 . CL/F increased by 46% in 100-kg individuals compared to 60-kg individuals and was found to be 21% higher in UGT2B7 rs7439366 TT individuals. These covariates explained 14% and 9% of the interindividual variability in CL/F, respectively. No influence of varenicline Cav was found on Kin in addition to the number of cigarettes. Body weight mostly and to a smaller extent genetic polymorphisms of UGT2B7 can influence varenicline exposure. Dose adjustment based on body weight and, if available, on UGT2B7 genotype might be useful to improve clinical efficacy and tolerability of varenicline.